Impact of COX2 genotype, ER status and body constitution on risk of early events in different treatment groups of breast cancer patients.
Bottom Line: The COX2 rs5277 (306G>C) polymorphism has been associated with inflammation-associated cancers.Minor allele(C) frequency was 16.1%.Chemotherapy-treated G/G-carriers with a breast volume ≥ 850 ml had an increased risk of early events irrespective of ER status, adjusted HR 8.99 (1.14-70.89).
Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.Show MeSH
Related in: MedlinePlus
Mentions: For all patients, rs5277 was not associated with early events ( Fig. 2a; Log Rank 1 df; p = 0.99). Similar results were observed when patients who had received preoperative treatment were included. In a multivariable model including the 570 patients who had not received preoperative treatment, the G/G genotype did not predict early events (HR 1.01; 95% CI 0.63–1.61; p = 0.97), adjusting for tumor size, axillary nodal involvement, age and histological grade III. Adding the use of endocrine treatment, chemotherapy and radiation treatment or WHR and breast volume (either as dichotomous or continuous variables) to the model did not affect the results.
Affiliation: Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.